PIK3CA MUTATIONS

Clinical trials for PIK3CA MUTATIONS explained in plain language.

Never miss a new study

Get alerted when new PIK3CA MUTATIONS trials appear

Sign up with your email to follow new studies for PIK3CA MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New targeted drug trial launches for Hard-to-Treat cancers

Disease control Not yet recruiting

This early-stage study is testing a new targeted drug called CGT6297 in adults with advanced solid tumors that have a specific genetic change called a PIK3CA mutation. The main goals are to find a safe dose and see if the drug shows early signs of helping to shrink tumors. The st…

Matched conditions: PIK3CA MUTATIONS

Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control

Last updated Mar 31, 2026 12:12 UTC

PIK3CA MUTATIONS

Get alerted when new PIK3CA MUTATIONS trials appear

New targeted drug trial launches for Hard-to-Treat cancers